WPD Pharmaceuticals Inc. (WBIO)

Overview

WPD Pharmaceuticals Inc. is a biotechnology research and development company with a focus on creating medicinal products within the oncology field. Headquartered in Vancouver, Canada, the company is dedicated to the discovery and development of novel treatments designed to combat various forms of cancer. Leveraging advanced research techniques and a deep understanding of oncological diseases, WPD Pharmaceuticals aims to provide innovative solutions to some of the most challenging cancer types affecting patients today.

Products and Services

• WPD101: This product is in development to address brain cancers. By targeting specific pathways or cells that contribute to the growth and proliferation of brain cancer, WPD101 aims to provide a targeted therapy option for patients suffering from this lethal disease.
• WPD102: Developed for the treatment of uveal melanoma, WPD102 focuses on a rare and aggressive form of eye cancer. This innovative approach aims to halt the progression of the disease, offering hope for better outcomes for patients affected by uveal melanoma.
• Berubicin: This promising compound is under development for the treatment of glioblastoma multiforme, one of the most aggressive and deadly forms of brain cancer. Berubicin represents a new hope for extending life expectancy and improving the quality of life for patients diagnosed with this condition.
• WP1066: Aimed at treating glioblastoma and melanoma brain metastases, WP1066 represents a new frontier in the fight against these formidable cancers. By targeting specific molecular pathways involved in the spread and growth of cancer cells, WP1066 endeavors to reduce tumor size and prevent further metastasis.
• WP1220: This product focuses on the treatment of cutaneous T-cell lymphoma, a type of skin cancer that can be both disfiguring and life-threatening. WP1220 is designed to target and eliminate cancer cells, providing relief and potentially a cure for patients suffering from this condition.
• WPD103: A radiopharmaceutical product based on the expression of tumor-specific receptors such as IL-13RA2 and EphA2. WPD103 represents a targeted approach to cancer therapy, aiming to deliver radioactive compounds directly to cancer cells, thus minimizing damage to healthy tissue.
• Annamycin: In development for the treatment of solid tumor metastases and specific cancer types including breast, ovarian, lung, and lower gastrointestinal tract cancers, Annamycin is a next-generation chemotherapy agent designed to overcome multi-drug resistance, a common challenge in cancer treatment.